Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propagermanium dose-escalation study in proteinuria on stable irbesartan
ACTRN12614001132639Phase 2Completed
- Sponsor
- Dimerix
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of repagermanium in proteinuria, sponsored by Dimerix. Primary endpoint: Safety and tolerability of propagermanium added to standard irbesartan. Started Sep 2015; status: completed.
02
Drugs
repagermanium
03
Conditions
proteinuria
Beyond the preview
Go deeper on ACTRN12614001132639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001132639.